Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9-10, 2009.
BACKGROUND
Prominent published and active human papillomavirus (HPV) modelers from around the world were invited to participate in the inaugural Modeling Evidence in HPV (MEHPV) Pre-Conference Workshop on May 9-10, 2009, in Malmö, Sweden. The workshop took place directly before the 25th International Papillomavirus Conference.


OBJECTIVE
The aim of the workshop was to develop an international network of investigators engaged in HPV modeling and to facilitate open discussion about the structure and parameterization of models, as well as other methodologic concerns.


METHODS
Thirty-four participants from more than a dozen countries and a variety of settings, representing the authors or coauthors of 82% of the HPV modeling literature, exchanged ideas on fundamental questions in the field. These proceedings, based on the 217-page transcript, were assembled by the Scientific Committee to summarize the ideas of workshop participants in a deidentified, readable fashion. They represent the work and recorded opinions of session participants and do not constitute the official positions of participants as a whole or individually, the Scientific Committee, or any sponsoring organization or entity.


RESULTS
In charting a path forward, 3 topics emerged as most pressing: best practices for HPV modeling, comparative modeling, and modeling in developing countries.


CONCLUSIONS
This summary of the proceedings of the preconference workshop on HPV modeling characterizes many of the prominent contemporary issues in the field.
Craig
Benjamin M
BM
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612-9416, USA. Benjamin.Craig@moffitt.org
Brisson
Marc
M
Chesson
Harrell
H
Giuliano
Anna R
AR
Jit
Mark
M
D032921:Consensus; D003906:Developing Countries; D005260:Female; D006801:Humans; D008297:Male; D008954:Models, Biological; D018803:Models, Economic; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control / Q000821:virology*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D019057:Quality-Adjusted Life Years
D053918:Papillomavirus Vaccines